ID   BLN-3
AC   CVCL_6G24
DR   EGA; EGAS00001001167
DR   DSMZ; ACC-787
DR   DSMZCellDive; ACC-787
DR   Wikidata; Q54797381
RX   PubMed=28148826;
CC   Doubling time: ~2-4 days (DSMZ=ACC-787).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28148826).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): DSMZ=ACC-787
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 13
ST   D16S539: 12,13
ST   D18S51: 12
ST   D19S433: 13,16
ST   D21S11: 27,29
ST   D2S1338: 20,23
ST   D3S1358: 14,17
ST   D5S818: 11,13
ST   D7S820: 11,12
ST   D8S1179: 10,13
ST   FGA: 23,26
ST   Penta D: 12,14
ST   Penta E: 7,10
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 19-12-24; Version: 11
//
RX   PubMed=28148826; DOI=10.1158/1541-7786.MCR-16-0322;
RA   Schulze Heuling E., Knab F., Radke J., Eskilsson E.,
RA   Martinez-Ledesma E., Koch A., Czabanka M., Dieterich C., Verhaak R.G.,
RA   Harms C., Euskirchen P.;
RT   "Prognostic relevance of tumor purity and interaction with MGMT
RT   methylation in glioblastoma.";
RL   Mol. Cancer Res. 15:532-540(2017).
//